BioSpace News Archive

Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced that five poster presentations highlighting data regarding its product portfolio will be presented at the 14th Annual PAINWeek National Conference taking place virtually September 11-13th.

Blueprint Medicines Corporation (NASDAQ:BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that Jeff Albers, Blueprint Medicines’ Chief Executive Officer, will participate virtually in a fireside chat at the 18th Annual Morgan Stanley Global Healthcare Conference

Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage biotechnology company developing transformational treatments for patients with non-alcoholic steatohepatitis (NASH) and other serious metabolic disorders, today announced that management will participate in a fireside chat at Morgan Stanley’s 18 th Annual Globa

MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today reported results for its fiscal year ended June 30, 2020.

Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present at the following virtual investor conferences: The H.C. Wainwright Annual Global Investment Conference on Monday, September 14,

NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today announced that the company’s management is scheduled to present at the Morgan Stanley Global Healthcare Conference. Brad Gray, president and chief executive officer, is scheduled to present on Monday, Septem

Forte Biosciences, Inc. ( www.fortebiorx.com ) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, today announced the publication in Science Translational Medicine of the full results of the Phase 1/2a data for its lead product candidate, FB-401. FB-401, a live biotherapeutic consisting of specifically selected strains of commensal Roseomonas mucosa , was studied in an open-label Phase 1/2a trial in atopi

Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that Savara management will be presenting at the H.C. Wainwright Annual Investment Conference on Wednesday, September 16, 2020 at 3:00 PM EDT/12:00 PM PDT. Interested parties can access a live audio webcast on the Investors page of the Sav

Sizable and growing market opportunity with over 78,000 patients receiving hemodialysis annually

Natera, Inc., a global leader in cell-free DNA testing, announced the launch of a proposed follow-on public offering of $250,000,000 of shares of its common stock.